A Phase 1 Dose Escalation Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Intravenous Doses of GSK2315698A in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs GSK 2315698 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 26 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Mar 2011 New trial record